Skip to content

Older adults and medical marijuana: Reduced stigma and increased use

Older adults and medical marijuana: Reduced stigma and increased use

As a primary care doctor who has incorporated medical cannabis into his practice, it is notable how many silver-haired patients are coming in to discuss the pros and cons of a trial of medical cannabis. These patients range from people in their 60s with kidney failure who can no longer take certain pain medications but still need to manage chronic pain, to patients in their 90s, who are looking for a good night’s sleep and are leery of the side effects of traditional sleep medications. Some of them — typically “children of the 60s” — are quite comfortable with the idea of using medical marijuana; others bring it up quietly, as if they are asking permission to break the law.

According to a recent study in the Journal of the American Medical Association, cannabis use among older adults (defined as 65 and older) in the US has been steadily increasing. In this study, the prevalence of past-year use increased from 2.4% to 4.2% from 2015 to 2018. This study is consistent with other research, as well as with reports from physicians who recommend cannabis in their daily practices.

What might be behind this trend?

Read Full Article Here

Stories you may be interested in

Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says

Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020. Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber…
Read More

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More

State Board of Health reviews timelines for establishing Mississippi medical marijuana program

JACKSON, Miss. (WLBT) – The blueprint for Mississippi’s medical marijuana program is Initiative 65 that voters approved in November. That contains detailed requirements and the clock is ticking to get it started. The State Board of Health met virtually Wednesday to discuss the groundwork of the medical marijuana program. “I do want to tell you…
Read More

July Updates

In our quest to save medical marijuana clinics valuable time, Arfinn Med has continued to release new functionality that improves EMR workflows.  This has led to the development of our new telehealth platform, new automated patient intake emails, and generating all state required documentation.  Continuing on our quest, we are proud to release our new…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

More baby boomers use medical marijuana, but they want their doctors to get wise to the risks and benefits

Baby boomers’ marijuana use has edged upward in the past decade, but recent research suggests some still have a hard time getting a hold of the drug. Older adults want more education, more research and greater openness with their health-care providers about using medical marijuana, according to a qualitative study of older cannabis users and non-users in…
Read More

Leave a Comment

You must be logged in to post a comment.